POST Online Media Lite Edition


Targovax appoints Damian Marron as chairman

Christian Fernsby |
Oslo, Norway - Targovax, a clinical stage biotechnology company, announces that its nomination committee has nominated Damian Marron for election as chairman of the board.

Article continues below

Mr. Marron is an experienced non-executive director, corporate advisor and life science executive with a successful track record of value creation through public and venture capital financing, portfolio planning, M&A, licensing agreements as well as R&D collaborations, both as an executive and in advisory roles.

Mr. Marron has notably specialized in immuno-oncology, cell therapy and orphan diseases.

Mr. Marron is currently Non-Executive Director at Bone Therapeutics a clinical stage, regenerative medicine company listed on Euronext and Resolys Bio, a private, late pre-clinical US startup.

He is also Head of Biopharma with Treehill Partners, a global pure-play healthcare advisory firm.


Airthings appoints Jeremy Gerst as CFO
Endúr appoints Jeppe Raaholt as CEO
Solon Eiendom appoints Finn Øistein Nordam as chief financial officer
Cermaq makes senior management appointments
Aker Solutions appoints Ole Martin Grimsrud as CFO